Agreement under authority 2373.

Active Other Transaction Agreement Awarded Last action

Contract number
W911QY2090003
Awardee
Awarding agency
Obligated
$146,790,129

Award facts

Contract value 77% obligated
  • $146,790,129.16 Current, with exercised options
  • $190,241,861.21 Potential, with all options
Completion date 91% complete
Current and potential, with all options
Funding agency
Joint PEO Chemical and Biological Defense Acquisition Support Center, Department of Defense
NAICS code
Not on record
Competition
Competed Broad Agency Announcement
Pricing
Other
Place of performance
Santa Fe, FL 32615, USA

Award details come from SAM.gov/FPDS.

Transactions

Action Obligated Date
Funding Only Action P00066 -$259,784
Terminate for Convenience P00065 $0
Other Administrative Action P00064 $0
Supplemental Agreement for work within scope P00063 $0
Funding Only Action P00062 $0
Supplemental Agreement for work within scope P00061 $0
Supplemental Agreement for work within scope P00060 · Developing and delivering a manufacturing platform that optimizes productivity and reduces manufacturing timelines for therapeutic monoclonal antibodies in… $401,426
Funding Only Action P00059 · Project 20-05: rapid MAB covid $1,320,549
Change Order P00058 $0
Supplemental Agreement for work within scope P00057 · Developing and delivering a manufacturing platform that optimizes productivity and reduces manufacturing timelines for therapeutic monocolonal antibodies in… $0
Change Order P00056 · Vero cell based manufacturing for ross river virus vaccine development. $0
Funding Only Action P00055 · Agreement for rapid monoclonal antibodies manufacturing system. $8,603,977
Funding Only Action P00054 · Rapid monoclonal antibodies manufacturing system agreement $1,000,000
Supplemental Agreement for work within scope P00053 $0
Change Order P00052 $0
Funding Only Action P00051 · Project 20-05: rapid MAB covid $1,000,000
Funding Only Action P00050 $1,922,097
Supplemental Agreement for work within scope P00049 · 4023 procurement project $0
Supplemental Agreement for work within scope P00048 · Procurement of developmental materials. $3,000,000
Funding Only Action P00047 · Vero cell supply $2,701,000
Supplemental Agreement for work within scope P00046 · USC 4023 MAB development $0
Other Administrative Action P00045 · Terminate project 20-07 only $0
Other Administrative Action P00044 · Prototype OTA for monoclonial development supplies $805,186
Supplemental Agreement for work within scope P00043 · 2373 material development $536,788
Supplemental Agreement for work within scope P00042 · Project 20-06 additional effort -$2,000,000
Supplemental Agreement for work within scope P00041 · Ology 2373 project agreement $0
Funding Only Action P00040 · Funds deobligation project 21-02 -$2,473,643
Supplemental Agreement for work within scope P00039 · No cost extension, correction to P00038 and revised 21-01 efforts. $0
Supplemental Agreement for work within scope P00038 · Incorporation of REV 3 of the SOW under project 20-08. $0
Supplemental Agreement for work within scope P00037 · P00037 was corrected to align with the PD2 version which was a funding deobligation action only. P00038 incorporates the additional SOW requirements. -$3,340,340
Supplemental Agreement for work within scope P00036 · Additional scope, incorporate covid-19 requirements for contractors. $0
Supplemental Agreement for work within scope P00035 · Project 20-02 vero cell in scope changes. $0
Supplemental Agreement for work within scope P00034 · "covid-19" additional scope for project 20-05 $4,189,969
Funding Only Action P00033 · Funding deobligation -$1,775,335
Funding Only Action P00032 · Incremental funding $722,368.11 and correct total funding amount to reflect current agreement value. $722,368
Supplemental Agreement for work within scope P00031 · Revision to appendix A7, burkhoderia OMV vaccine. $4,466,215
Supplemental Agreement for work within scope P00030 · "covid-19" change in effort to align with requirements. -$855,962
Supplemental Agreement for work within scope P00029 · "covid-19" deobligate effort under clin 0010, remove funding. -$5,035,328
Supplemental Agreement for work within scope P00028 · "covid-19" VLP manufacturing capability $4,600,000
Supplemental Agreement for work within scope P00027 · Incorporation of minimum yield for the projects. -$3,719,176
Other Administrative Action P00026 · Incorporate revisions to appendix a-5. $0
Supplemental Agreement for work within scope P00025 · "covid-19" reduction of scope under project 20-05. -$5,058,127
Supplemental Agreement for work within scope P00024 · "covid-19" mabs manufacturing system, project 20-04 $0
Supplemental Agreement for work within scope P00023 · "coivid-19" mabs manufacturing system. $16,604,877
Supplemental Agreement for work within scope P00022 · Additional effort under clin 0008 and funding under clin 0005. $650,000
Funding Only Action P00020 · "covid-19" incremental funding $5,000,000
Change Order P00021 · Project 20-01 stop work notification $0
Supplemental Agreement for work within scope P00018 · "covid-19" indirect rate adjustment $0
Supplemental Agreement for work within scope P00017 · "covid-19" additional development under project 20-03. $1,248,193
Other Administrative Action P00016 · Deobligation and incorporation of revised article 15 -$1,000,000
Show 40 more

Latest 50 listed here. See the rest on GovTribe.

About this award

The U.S. Department of Defense's Joint Program Executive Office (PEO) for Chemical and Biological Defense awarded Resilience Government Services, Inc. (doing business as Nanotherapeutics Inc.) an Other Transaction Agreement valued at $190.2 million on February 21, 2020. Under this agreement, which is scheduled for completion by June 14, 2027, Resilience will develop and deliver an advanced manufacturing platform designed to optimize productivity and reduce manufacturing timelines for therapeutic monoclonal antibodies in response scenarios. The work will be performed in Alachua, Florida, and represents a critical capability for the Chemical and Biological Defense program's medical countermeasure development initiatives. The contract carries no small business set-aside designation.

Resilience Government Services is a biomanufacturing company founded in 2020 that specializes in end-to-end manufacturing solutions for complex medicines and therapeutics. The company has demonstrated experience across multiple Department of Defense and Department of Health and Human Services programs, delivering capabilities spanning from early-stage research and process development through late-stage product development and FDA licensure support. This agreement complements Resilience's existing portfolio of active Indefinite Delivery Vehicles, including a $5.7 million Other Transaction IDIQ and a $249 million single-award Indefinite Delivery Contract focused on FDA-approved products supporting chemical and biological defense initiatives.

Quick answers

Who was awarded contract W911QY2090003?

W911QY2090003 was awarded to Resilience Government Services, Inc. by ACC Aberdeen Proving Ground (Army Contracting Command) on February 21, 2020.

How much is contract W911QY2090003 worth?

The government has obligated $146,790,129 on W911QY2090003. Its potential value, with all options, is $190,241,861.

Which agency awarded contract W911QY2090003?

ACC Aberdeen Proving Ground (Army Contracting Command) awarded W911QY2090003, with funding from Joint PEO Chemical and Biological Defense (Acquisition Support Center).

Was contract W911QY2090003 competed?

The extent of competition for W911QY2090003 was competed.

On GovTribe

See this award's full record

  • Every transaction and funding action
  • The awardee's other awards and teaming partners
  • Similar awards and recompete opportunities
  • Ask GovTribe AI about this award